286 related articles for article (PubMed ID: 19108713)
1. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients.
Zhang M; Song T; Yang L; Chen R; Wu L; Yang Z; Fang J
J Exp Clin Cancer Res; 2008 Dec; 27(1):85. PubMed ID: 19108713
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of clinical factors and cancer stem cell-related markers in gliomas.
Dahlrot RH
Dan Med J; 2014 Oct; 61(10):B4944. PubMed ID: 25283629
[TBL] [Abstract][Full Text] [Related]
3. [Correlative study of distribution of brain tumor stem cell with micro-vascular system].
Li MW; Niu CS
Zhonghua Yi Xue Za Zhi; 2010 Feb; 90(5):305-9. PubMed ID: 20368050
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
Dahlrot RH; Hansen S; Jensen SS; Schrøder HD; Hjelmborg J; Kristensen BW
Int J Clin Exp Pathol; 2014; 7(7):3739-51. PubMed ID: 25120750
[TBL] [Abstract][Full Text] [Related]
5. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
Wu B; Sun C; Feng F; Ge M; Xia L
J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
[TBL] [Abstract][Full Text] [Related]
6. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas.
Kim KJ; Lee KH; Kim HS; Moon KS; Jung TY; Jung S; Lee MC
Neuropathology; 2011 Oct; 31(5):494-502. PubMed ID: 21269333
[TBL] [Abstract][Full Text] [Related]
7. What is the clinical value of cancer stem cell markers in gliomas?
Dahlrot RH; Hermansen SK; Hansen S; Kristensen BW
Int J Clin Exp Pathol; 2013; 6(3):334-48. PubMed ID: 23412423
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD133 and other putative stem cell markers in uveal melanoma.
Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM
Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792
[TBL] [Abstract][Full Text] [Related]
9. The pathological characteristics of glioma stem cell niches.
He H; Li MW; Niu CS
J Clin Neurosci; 2012 Jan; 19(1):121-7. PubMed ID: 22178090
[TBL] [Abstract][Full Text] [Related]
10. Glioma cell populations grouped by different cell type markers drive brain tumor growth.
Prestegarden L; Svendsen A; Wang J; Sleire L; Skaftnesmo KO; Bjerkvig R; Yan T; Askland L; Persson A; Sakariassen PØ; Enger PØ
Cancer Res; 2010 Jun; 70(11):4274-9. PubMed ID: 20460538
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of stem cell marker CD133 determined by promoter methylation but not by immunohistochemical expression in malignant gliomas.
Wu X; Wu F; Xu D; Zhang T
J Neurooncol; 2016 Apr; 127(2):221-32. PubMed ID: 26757925
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic value of JAM-A in gliomas.
Rosager AM; Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Lathia JD; Kristensen BW
J Neurooncol; 2017 Oct; 135(1):107-117. PubMed ID: 28677106
[TBL] [Abstract][Full Text] [Related]
13. Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines.
Veselska R; Hermanova M; Loja T; Chlapek P; Zambo I; Vesely K; Zitterbart K; Sterba J
BMC Cancer; 2008 Oct; 8():300. PubMed ID: 18925963
[TBL] [Abstract][Full Text] [Related]
14. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.
Tamura K; Aoyagi M; Ando N; Ogishima T; Wakimoto H; Yamamoto M; Ohno K
J Neurosurg; 2013 Nov; 119(5):1145-55. PubMed ID: 23991844
[TBL] [Abstract][Full Text] [Related]
15. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance.
Kim HS; Yoo SY; Kim KT; Park JT; Kim HJ; Kim JC
Int J Clin Exp Pathol; 2012; 5(8):754-61. PubMed ID: 23071857
[TBL] [Abstract][Full Text] [Related]
16. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas.
Bexell D; Gunnarsson S; Siesjö P; Bengzon J; Darabi A
Int J Cancer; 2009 Jul; 125(1):15-22. PubMed ID: 19291792
[TBL] [Abstract][Full Text] [Related]
17. The stem cell marker nestin predicts poor prognosis in human melanoma.
Piras F; Perra MT; Murtas D; Minerba L; Floris C; Maxia C; Demurtas P; Ugalde J; Ribatti D; Sirigu P
Oncol Rep; 2010 Jan; 23(1):17-24. PubMed ID: 19956860
[TBL] [Abstract][Full Text] [Related]
18. Stem cell marker CD133 affects clinical outcome in glioma patients.
Zeppernick F; Ahmadi R; Campos B; Dictus C; Helmke BM; Becker N; Lichter P; Unterberg A; Radlwimmer B; Herold-Mende CC
Clin Cancer Res; 2008 Jan; 14(1):123-9. PubMed ID: 18172261
[TBL] [Abstract][Full Text] [Related]
19. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas.
He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H
Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436
[TBL] [Abstract][Full Text] [Related]
20. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors.
Beier D; Wischhusen J; Dietmaier W; Hau P; Proescholdt M; Brawanski A; Bogdahn U; Beier CP
Brain Pathol; 2008 Jul; 18(3):370-7. PubMed ID: 18371181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]